References
- Grandi G, Ferrari S, Xholli A, et al. Prevalence of menstrual pain in young women: what is dysmenorrhea? J Pain Res 2012;5:169–74
- Zahradnik HP, Hanjalic-Beck A, Groth K. Nonsteroidal anti-inflammatory drugs and hormonal contraceptives for pain relief from dysmenorrhea: a review. Contraception 2010;81:185–96
- Wong CL, Farquhar C, Roberts H, Proctor M. Oral contraceptive pill for primary dysmenorrhea. Cochrane Database Syst Rev 2009;7:CD002120
- Hanjalic-Beck A, Schäfer WR, Deppert WR, et al. Chlormadinone acetate suppresses prostaglandin biosynthesis in human endometrial explants. Fertil Steril 2012;98:1017–22
- Schramm GA, Schrah G. The efficacy and safety of an oral contraceptive containing chlormadinone acetate: results of a pooled analysis of noninterventional trials in adult and adolescent women. Contraception 2011;84:390–401
- Hadji P, Biskup J, Boekhoff J, et al. Evaluation of efficacy, safety and effects on symptoms of androgenisation of a generic oral contraceptive containing chlormadinone acetate 2 mg/ethinylestradiol 0.03 mg. Contraception 2012;86:359–65
- Yang LP, Plosker GL. Nomegestrol acetate/estradiol: in oral contraception. Drugs 2012;72:1917–28
- Creinin MD, Witjes H, Korver T. Nomegestrol acetate and 17β-estradiol reduces menstrual symptoms, pain, and cramps compared with drospirenone and ethinylestradiol: a pooled analysis. Obstet Gynecol 2014;123:105S
- World Health Organization (WHO). Medical eligibility criteria for contraceptive use. 4th ed. Geneva, Switzerland: WHO; 2009
- Grandi G, Xholli A, Ferrari S, et al. Intermenstrual pelvic pain, quality of life and mood. Gynecol Obstet Invest 2013;75:97–100
- Ware JE Jr, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). Conceptual framework and item selection. Med Care 1992;30:473–83
- Harada T, Momoeda M, Terakawa N, et al. Evaluation of a low-dose oral contraceptive pill for primary dysmenorrhea: a placebo-controlled, double-blind, randomized trial. Fertil Steril 2011;95:1928–31
- Schramm G, Heckes B. Switching hormonal contraceptives to a chlormadinone acetate-containing oral contraceptive. The Contraceptive Switch Study. Contraception 2007;76:84–90
- Sabatini R, Orsini G, Cagiano R, Loverro G. Noncontraceptive benefits of two combined oral contraceptives with antiandrogenic properties among adolescents. Contraception 2007;76:342–7
- Read CM. New regimens with combined oral contraceptive pills–moving away from traditional 21/7 cycles. Eur J Contracept Reprod Health Care 2010;15:S32–41
- Grandi G, Piacenti I, Volpe A, Cagnacci A. Modification of body composition and metabolism during oral contraceptives containing non-androgenic progestins in association with estradiol or ethinyl-estradiol. Gynecol Endocrinol 2014;30:676–80
- Cagnacci A, Ferrari S, Tirelli A, Zanin R, Volpe A. Insulin sensitivity and lipid metabolism with oral contraceptives containing chlormadinone acetate or desogestrel: a randomized trial. Contraception 2009;79:111–16
- Ågren UM, Anttila M, Mäenpää-Liukko K, et al. Effects of a monophasic combined oral contraceptive containing nomegestrol acetate and 17β-oestradiol compared with one containing levonorgestrel and ethinylestradiol on haemostasis, lipids and carbohydrate metabolism. Eur J Contracept Reprod Health Care 2011;16:444–57
- Basdevant A, Pelissier C, Conard J, et al. Effects of nomegestrol acetate (5 mg/d) on hormonal, metabolic and hemostatic parameters in premenopausal women. Contraception 1991;44:599–605